A new formulation of Xgeva (denosumab) is the first product to be authorized by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) via the regulator’s new International Recognition Procedure (IRP).
Amgen’s (Nasdaq: AMGN) product is used for preventing serious bone-related complications caused by bone metastasis and treating giant cell tumor of bone.
"This new international agreement allows treatments to be approved more quickly by drawing on expertise from partners across the world"The product was authorized in 30 days, providing UK patients with earlier access to this treatment thanks to international recognition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze